Isolagen Inc announced that the U.S. Patent Office issued Patent No. 6,432,710 entitled "Compositions for regenerating tissue that has deteriorated and methods for using such compositions" to the Company.

The Company believes the importance of this invention could represent a significant breakthrough in the treatment of periodontal defects. "With our new patent, Isolagen can move forward with its focus on commercialising bioresorbable matrices saturated with autologous cells to enhance the regeneration of periodontal tissue," said Michael Macaluso, Chief Executive Officer. Autologous simply means "the patient's own." Our initial focus will be the treatment and restoration of gingival tissue in the interdental regions (between teeth) using autologous oral mucosal fibroblasts. We will also explore areas of gum recession and recession after root planning or periodontal surgery.

The dental patient's autologous cells are obtained by a simple one (1) mm biopsy taken from the oral cavity. The biopsy is sent to the Isolagen lab where the cells are propagated to a new population of over 50 million cells. The cells are then delivered to the patient's area of treatment by their doctor. The use of your own cells eliminates the need for donor skin taken from the palate, or using foreign substances to cover the recession.

The Company believes that the upcoming pilot study conducted at UTHSC by Drs. Otis Bouwsma and Rena D'Souza will validate Isolagen's research and will enable Isolagen to commercialize in countries where the Isolagen Process is approved.